Trillium Therapeutics Inc on Focus After Crashing In Today’s Session

 Trillium Therapeutics Inc on Focus After Crashing In Today's Session

The stock of Trillium Therapeutics Inc (TSE:TR) is a huge mover today! About 19,327 shares traded hands. Trillium Therapeutics Inc (TSE:TR) has declined 31.28% since April 27, 2016 and is downtrending. It has underperformed by 37.20% the S&P500.
The move comes after 6 months negative chart setup for the $71.77M company. It was reported on Dec, 1 by Barchart.com. We have $8.94 PT which if reached, will make TSE:TR worth $5.74M less.

More recent Trillium Therapeutics Inc (TSE:TR) news were published by: Marketwatch.com which released: “Trillium Therapeutics Inc.” on August 24, 2009. Also Etfdailynews.com published the news titled: “Trillium Therapeutics Inc. (TRIL): Finding The Next Blockbuster Biotech Stock” on June 23, 2015. Quotes.Wsj.com‘s news article titled: “News Trillium Therapeutics Inc.TRIL” with publication date: December 20, 2014 was also an interesting one.

Trillium Therapeutics Inc is a Canada clinical stage immuno-oncology firm developing therapies for the treatment of cancer. The company has a market cap of $71.77 million. The Company’s SIRPaFc program, which is under Phase I clinical trial, is a fusion protein that consists of the CD47-binding domain of human SIRPa linked to the fragment crystallizable (Fc) region of a human immunoglobulin (IgG1). It currently has negative earnings. It acts as a soluble decoy receptor, preventing CD47 from delivering its inhibitory signal.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment